US 9,809,581 B2
Inhibitors of CXCR2
Xi Chen, E. Palo Alto, CA (US); Dean R. Dragoli, Los Altos, CA (US); Junfa Fan, Palo Alto, CA (US); Jaroslaw Kalisiak, Mountain View, CA (US); Manmohan Reddy Leleti, San Jose, CA (US); Viengkham Malathong, Mountain View, CA (US); Jeffrey McMahon, San Francisco, CA (US); Hiroko Tanaka, Mountain View, CA (US); Ju Yang, Palo Alto, CA (US); Chao Yu, Sunnyvale, CA (US); Penglie Zhang, Foster City, CA (US); and Venkat Mali, Cupertino, CA (US)
Assigned to ChemoCentryx, Inc., Mountain View, CA (US)
Filed by CHEMOCENTRYX, INC., Mountain View, CA (US)
Filed on Nov. 17, 2016, as Appl. No. 15/353,949.
Claims priority of provisional application 62/257,529, filed on Nov. 19, 2015.
Prior Publication US 2017/0144996 A1, May 25, 2017
Int. Cl. C07D 405/12 (2006.01); A61K 31/4035 (2006.01); C07D 405/14 (2006.01); C07B 59/00 (2006.01); A61K 45/06 (2006.01); A61K 31/4439 (2006.01); A61K 31/422 (2006.01); C07D 413/12 (2006.01)
CPC C07D 405/12 (2013.01) [A61K 31/4035 (2013.01); A61K 31/422 (2013.01); A61K 31/4439 (2013.01); A61K 45/06 (2013.01); C07B 59/002 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07B 2200/05 (2013.01)] 29 Claims
 
1. A compound having formula (I):

OG Complex Work Unit Drawing
wherein
R1 and R2 are each members independently selected from the group consisting of H, halogen, CN, C1-4 alkyl, C1-4 alkoxy and C1-4 haloalkyl;
R3a is a member selected from the group consisting of methyl, ethyl, propyl, isopropyl, trifluoromethyl, CH2CF3 and CF2CF3;
R3b is a member selected from the group consisting of H and D;
R4 is a member selected from the group consisting of H, C1-8 alkyl, —Y and C1-4alkylene-Y;
wherein Y is aryl or heteroaryl, and each R4 is optionally substituted with from one to four substituents selected from the group consisting of halogen, —CN, —CO2Ra, —CONRaRb, —C(O)Ra, —OC(O)NRaRb, —NRaC(O)Rb, —NRaC(O)2Rc, —NRaC(O)NRaRb, —NRaRb, —ORa, —S(O)2NRaRb, —NRaS(O)2Rb, and —Rc,
wherein each Ra and Rb is independently selected from hydrogen, C1-4 alkyl, C1-4 hydroxyalkyl and C1-4 haloalkyl, and Rc is selected from C1-4 alkyl; C1-4 hydroxyalkyl and C1-4 haloalkyl;
R5a and R5b are each members independently selected from the group consisting of H, halogen, C1-4 alkyl, C1-4 alkoxy and CN;
R6a and R6b are each members independently selected from the group consisting of H, C1-4 alkyl, C1-4 hydroxyalkyl and C1-4 haloalkyl; or optionally R6a and R6b are taken together to form oxo (═O);
X is CH or N;
or any salts, solvates, hydrates, N-oxides, tautomers or rotamers thereof.